Search Results 1131-1140 of 16379 for anti-TNF drugs

1. Crotalidae immune f(ab)2 (equine) (intravenous route) - Side effects & uses - Mayo Clinic

   Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Drug Interactions. Although certain medicines should ...

2. Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer - Mayo Clinic

   By condition, treatment or drug name. Search ... agents, corticosteroids or immunosuppressive drugs). ... anti-HBc [antibody to hepatitis B core antigen] ...

3. A Study of DCC-2618 vs. Sunitinib in Advanced GIST Patients after Treatment with Imatinib - Mayo Clinic

   NOTE: Patients with a history of breast cancer, requiring continued hormonal treatment (e.g. anti-estrogen or an aromatase inhibitor) may continue treatment.

4. A Study to Compare Nivolumab or Brentuximab Vedotin Plus Combination Chemotherapy to Treat Patients with Newly-diagnosed Stage III-IV Classic Hodgkin Lymphoma - Mayo Clinic

   Drugs used in chemotherapy, such as doxorubicin, vinblastine ... Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy ...

5. Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis - Mayo Clinic

   Drugs & Supplements A-Z · Health Books · Healthy Living Program · Mayo Clinic ... By condition, treatment or drug name. Search tips. Comparison of Anti- ...

6. Viral Therapy in Treating Patients with Recurrent Glioblastoma Multiforme - Mayo Clinic

   Anti-measles virus immunity as demonstrated by IgG anti-measles antibody levels of ≥ 20 EU/ml as determined by Enzyme Immunoassay; Grade 3 astrocytoma ...

7. Immune checkpoint inhibitors and thyroid dysfunction: A case from the endocrine teaching clinics - Mayo Clinic

   Occasionally, a low TSH may indicate the presence of a central process consistent with immune therapy-induced hypophysitis. Hypophysitis is uncommon with anti- ...

8. Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer - Mayo Clinic

   - NOTE: Dose reductions or delays are permitted. - Greater than 90 days has elapsed between the most recent treatment with an anti-EGFR therapy (cetuximab ...

9. A Study to Evaluate TVB-2640 and Trastuzumab Plus Paclitaxel or Endocrine Therapy for Treating Patients with HER2 Positive Advanced Breast Cancer - Mayo Clinic

   Distant disease progression during administration of combination therapy with endocrine therapy and anti-HER2 therapy (trastuzumab or pertuzumab) for metastatic ...

10. Treatment outcomes

    Stroke Core Measure · Carotid Endarterectomy Mortality · Carotid Stenting Mortality · Comprehensive Stroke Measure · Comprehensive Stroke – Arrival Time to Skin ...